Mitumomab

米妥莫单抗

Report date: 2023/04/25 13:58:50

Base Information

Drug NameMitumomab
Drug Alias NameAnti-idiotype cancer vaccine - ImClone Systems/Merck KGaAMonoclonal antibody BEC-2IMC-BEC2LuVaxMelVax +[6] 
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsGanglioside GD3
Therapy Area/IndicationsSmall Cell Lung Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesImclone Systems
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsSmall Cell Lung Carcinoma

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG